Close

RedHill Biopharma (RDHL) Tops Q2 EPS by 52c, Beats on Revenues

July 25, 2017 7:05 AM EDT

RedHill Biopharma (NASDAQ: RDHL) reported Q2 EPS of ($0.06), $0.52 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $483 thousand versus the consensus estimate of $220 thousand.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings